Terms: = Pancreatic cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Treatment
73 results:
1. Unraveling the impact of cancer-associated fibroblasts on hypovascular pancreatic neuroendocrine tumors.
Lai TY; Chiang TC; Lee CY; Kuo TC; Wu CH; Chen YI; Hu CM; Maskey M; Tang SC; Jeng YM; Tien YW; Lee EYP; Lee WH
Br J Cancer; 2024 Apr; 130(7):1096-1108. PubMed ID: 38341509
[TBL] [Abstract] [Full Text] [Related]
2. Motixafortide: First Approval.
Hoy SM
Drugs; 2023 Nov; 83(17):1635-1643. PubMed ID: 37996648
[TBL] [Abstract] [Full Text] [Related]
3. The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art.
Lu G; Wang X; Cheng M; Wang S; Ma K
Biomed Pharmacother; 2023 Sep; 165():115132. PubMed ID: 37423169
[TBL] [Abstract] [Full Text] [Related]
4. Impact of cxcr4-Directed PET/CT on Staging and Proposed Oncologic Management in Patients With Digestive System Tumors.
Weich A; Serfling SE; Schlötelburg W; Higuchi T; Hartrampf PE; Schirbel A; Heinrich M; Buck AK; Rowe SP; Kosmala A; Werner RA
Clin Nucl Med; 2023 Jul; 48(7):586-593. PubMed ID: 37167408
[TBL] [Abstract] [Full Text] [Related]
5. Effect of tocopherol conjugation on polycation-mediated siRNA delivery to orthotopic pancreatic tumors.
Tang S; Kapoor E; Ding L; Yu A; Tang W; Hang Y; Smith LM; Sil D; Oupický D
Biomater Adv; 2023 Feb; 145():213236. PubMed ID: 36512927
[TBL] [Abstract] [Full Text] [Related]
6. cxcr4-CXCL12-CXCR7 and PD-1/PD-L1 in pancreatic cancer: CXCL12 Predicts Survival of Radically Resected Patients.
D'Alterio C; Giardino A; Scognamiglio G; Butturini G; Portella L; Guardascione G; Frigerio I; Montella M; Gobbo S; Martignoni G; Napolitano V; De Vita F; Tatangelo F; Franco R; Scala S
Cells; 2022 Oct; 11(21):. PubMed ID: 36359736
[TBL] [Abstract] [Full Text] [Related]
7. Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and cxcr4.
Hao S; Xu S; Li L; Li Y; Zhao M; Chen J; Zhu S; Xie Y; Jiang H; Zhu J; Wu M
BMC Cancer; 2022 Oct; 22(1):1092. PubMed ID: 36284271
[TBL] [Abstract] [Full Text] [Related]
8. Dual Stromal Targeting Sensitizes pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy.
Blair AB; Wang J; Davelaar J; Baker A; Li K; Niu N; Wang J; Shao Y; Funes V; Li P; Pachter JA; Maneval DC; Dezem F; Plummer J; Chan KS; Gong J; Hendifar AE; Pandol SJ; Burkhart R; Zhang Y; Zheng L; Osipov A
Gastroenterology; 2022 Nov; 163(5):1267-1280.e7. PubMed ID: 35718227
[TBL] [Abstract] [Full Text] [Related]
9. cxcr4 expression in tumor associated cells in blood is prognostic for progression and survival in pancreatic cancer.
Gardner KP; Tsai S; Aldakkak M; Gironda S; Adams DL
PLoS One; 2022; 17(3):e0264763. PubMed ID: 35259193
[TBL] [Abstract] [Full Text] [Related]
10. Nanoemulsion-Assisted siRNA Delivery to Modulate the Nervous Tumor Microenvironment in the treatment of pancreatic cancer.
Ding L; Tang S; Yu A; Wang A; Tang W; Jia H; Oupický D
ACS Appl Mater Interfaces; 2022 Mar; 14(8):10015-10029. PubMed ID: 35188730
[TBL] [Abstract] [Full Text] [Related]
11. Enhanced CXCL12/cxcr4 signaling increases tumor progression in radiation‑resistant pancreatic cancer.
Kato T; Matsuo Y; Ueda G; Murase H; Aoyama Y; Omi K; Hayashi Y; Imafuji H; Saito K; Morimoto M; Ogawa R; Takahashi H; Takiguchi S
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35119076
[TBL] [Abstract] [Full Text] [Related]
12. Circulating MiR-1290 as a potential diagnostic and disease monitoring biomarker of human gastrointestinal tumors.
Xu L; Cai Y; Chen X; Zhu Y; Cai J
BMC Cancer; 2021 Sep; 21(1):989. PubMed ID: 34479528
[TBL] [Abstract] [Full Text] [Related]
13. Synthesis and Therapeutic Potential of Nanoceria against cancer: An Update.
Zahra D; Javaid A; Iqbal M; Akbar I; Ashfaq UA
Crit Rev Ther Drug Carrier Syst; 2021; 38(5):1-26. PubMed ID: 34375511
[TBL] [Abstract] [Full Text] [Related]
14. Optimization strategy of Bacillus subtilis MT453867 levansucrase and evaluation of levan role in pancreatic cancer treatment.
Gamal AA; Abbas HY; Abdelwahed NAM; Kashef MT; Mahmoud K; Esawy MA; Ramadan MA
Int J Biol Macromol; 2021 Jul; 182():1590-1601. PubMed ID: 34015407
[TBL] [Abstract] [Full Text] [Related]
15. Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far.
Wong W; Alouani E; Wei A; Ryu YK; Chabot JA; Manji GA
Semin Oncol; 2021 Feb; 48(1):57-68. PubMed ID: 33965249
[TBL] [Abstract] [Full Text] [Related]
16. Polycation fluorination improves intraperitoneal siRNA delivery in metastatic pancreatic cancer.
Hang Y; Tang S; Tang W; Větvička D; Zhang C; Xie Y; Yu F; Yu A; Sil D; Li J; Singh RK; Oupický D
J Control Release; 2021 May; 333():139-150. PubMed ID: 33774121
[TBL] [Abstract] [Full Text] [Related]
17. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
Majidpoor J; Mortezaee K
Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
[TBL] [Abstract] [Full Text] [Related]
18. α1,6-Fucosyltransferase contributes to cell migration and proliferation as well as to cancer stemness features in pancreatic carcinoma.
Liang C; Fukuda T; Isaji T; Duan C; Song W; Wang Y; Gu J
Biochim Biophys Acta Gen Subj; 2021 Jun; 1865(6):129870. PubMed ID: 33571582
[TBL] [Abstract] [Full Text] [Related]
19. Combination treatment with VPA and MSCs‑TRAIL could increase anti‑tumor effects against intracranial glioma.
Park SA; Han HR; Ahn S; Ryu CH; Jeun SS
Oncol Rep; 2021 Mar; 45(3):869-878. PubMed ID: 33469674
[TBL] [Abstract] [Full Text] [Related]
20. cancer Stem Cell Markers in Relation to Patient Survival Outcomes: Lessons for Integrative Diagnostics and Next-Generation Anticancer Drug Development.
Dzobo K; Ganz C; Thomford NE; Senthebane DA
OMICS; 2021 Feb; 25(2):81-92. PubMed ID: 33170084
[TBL] [Abstract] [Full Text] [Related]
[Next]
